498 related articles for article (PubMed ID: 25861829)
1. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
2. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
3. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
5. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
Sperling AS; Gibson CJ; Ebert BL
Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
[TBL] [Abstract][Full Text] [Related]
6. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
7. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia.
Kröger N; Eikema DJ; Köster L; Beelen D; de Wreede LC; Finke J; Koenecke C; Niederwieser D; Bornhäuser M; Schoenland S; Potter V; Wolschke C; Maertens J; Theobald M; Kobbe G; Itälä-Remes M; Wulf G; Kahls P; Forcade E; Greinix H; Masszi T; Yakoub-Agha I; Chalandon Y; Robin M;
Br J Haematol; 2019 May; 185(4):725-732. PubMed ID: 30820933
[TBL] [Abstract][Full Text] [Related]
8. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes.
Kekre N; Koreth J
Curr Opin Hematol; 2015 Mar; 22(2):116-22. PubMed ID: 25575033
[TBL] [Abstract][Full Text] [Related]
9. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
10. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
11. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
[TBL] [Abstract][Full Text] [Related]
12. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
Ye X; Chen D; Zheng Y; Wu C; Zhu X; Huang J
Hematol Oncol; 2019 Oct; 37(4):438-446. PubMed ID: 31378958
[TBL] [Abstract][Full Text] [Related]
13. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.
Bauer M; Vaxevanis C; Heimer N; Al-Ali HK; Jaekel N; Bachmann M; Wickenhauser C; Seliger B
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992663
[TBL] [Abstract][Full Text] [Related]
14. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
16. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
[TBL] [Abstract][Full Text] [Related]
17. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
18. [Myelodysplastic syndromes: preleukemic syndromes].
Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
[TBL] [Abstract][Full Text] [Related]
19. What biologic factors predict for transformation to AML?
Bejar R
Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; Megías-Vericat JE; Serrano J; Martínez-Sánchez P; Rodríguez-Arbolí E; Gil C; Aguiar E; Bergua J; López-Lorenzo JL; Bernal T; Espadana A; Colorado M; Rodríguez-Medina C; López-Pavía M; Tormo M; Algarra L; Amigo ML; Sayas MJ; Labrador J; Rodríguez-Gutiérrez JI; Benavente C; Costilla-Barriga L; García-Boyero R; Lavilla-Rubira E; Vives S; Herrera P; García-Belmonte D; Herráez MM; Vasconcelos Esteves G; Gómez-Roncero MI; Cabello A; Bautista G; Balerdi A; Mariz J; Boluda B; Sanz MÁ; Montesinos P
Blood Adv; 2022 Feb; 6(4):1278-1295. PubMed ID: 34794172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
